Determining linezolid's baseline in vitro activity in Canada using gram-positive clinical isolates collected prior to its national release

Antimicrobial Agents and Chemotherapy

Volumn 46, Issue 6, 2002, Pages 1989-1992

  Karlowsky, James A ^a   Kelly, Laurie J ^a   Critchley, Ian A ^a   Jones, Mark E ^a   Thornsberry, Clyde ^a   Sahm, Daniel F ^a  

^a Focus Technologies Incorporated   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; CEFTRIAXONE; CEFUROXIME; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; ERYTHROMYCIN; GENTAMICIN; LEVOFLOXACIN; LINEZOLID; NITROFURANTOIN; OXACILLIN; PENICILLIN G; TEICOPLANIN; TETRACYCLINE; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CANADA; CONTROLLED STUDY; DRUG APPROVAL; DRUG UTILIZATION; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PENICILLIN RESISTANCE; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STREPTOCOCCUS PNEUMONIAE;

ACETAMIDES; ANTI-BACTERIAL AGENTS; CANADA; DRUG APPROVAL; DRUG RESISTANCE; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; OXAZOLIDINONES;

EID: 0036090638     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.46.6.1989-1992.2002     Document Type: Article

References (28)

1. In vitro activity of linezolid against multiply resistant gram-positive clinical isolates
2. Linezolid
3. In vitro activities of new oxazolidinone antimicrobial agents against enterococci
4. Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid
5. Surveillance of invasive Streptococcus pneumoniae infection in the province of Quebec, Canada, from 1996 to 1998: Serotype distribution, antimicrobial susceptibility, and clinical characteristics
6. Comparative activities of clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, ofloxacin, sparfloxacin, and trovafloxacin and non-quinolones linezolid, quinupristin-dalfopristin, gentamicin, and vancomycin against clinical isolates of ciprofloxacin-resistant and -susceptible Staphylococcus aureus strains
7. In vitro antimicrobial activities and spectra of U-100592 and U-100766, two novel fluorinated oxazolidinones
8. In vitro activities of oxazolidinone compounds C100592 and U100766 against Staphylococcus aureus and Staphylococcus epidermidis
9. Resistance mutations in 23S rRNA identify the site of action of the protein synthesis inhibitor linezolid in the ribosomal peptidyl transferase center
10. The oxazolidinone eperezolid binds to the 50S ribosomal subunit and competes with binding of chloramphenicol and lincomycin
11. Staphylococcus infections
12. National Nosocomial Infections Surveillance (NNIS) System report, data summary from January 1992-April 2000, issued June 2000
13. In vitro activities of linezolid against important gram-positive bacterial pathogens including vancomycin-resistant enterococci
14. In vitro activity of linezolid against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae
15. Resistance to linezolid: Characterization of mutations in rRNA and comparison of their occurrences in vancomycin-resistant enterococci
16. Vancomycin-resistant enterococci in health care facilities
17. In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against staphylococci and enterococci, including vancomycin-intermediate and -resistant strains
18. Need for annual surveillance of antimicrobial resistance in Streptococcus pneumoniae in the United States: 2-year longitudinal analysis
19. Mechanism of action of oxazolidinones: Effects of linezolid and eperezolid on translation reactions
20. The Canadian Nosocomial Infection Surveillance Program Health Canada. The evolution of methicillin-resistant Staphylococcus aureus in Canadian hospitals: 5 years of national surveillance
21. The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria
22. Linezolid resistance in a clinical isolate of Staphylococcus aureus
23. The in-vitro activity of linezolid (U-100766) and tentative breakpoints
24. Oxazolidinone resistance mutations in 23S rRNA of Escherichia coli reveal the central region of domain V as the primary site of drug action
25. In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents